End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice.
Journal of Clinical Oncology.
Times cited: 150
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Supportive Care in Cancer.
Times cited: 98